



DIVISION OF PUBLIC HEALTH

Jim Doyle
Governor

1 WEST WILSON STREET
P O BOX 2659
MADISON WI 53701-2659

Karen E. Timberlake
Secretary

State of Wisconsin
Department of Health Services

608-267-4797
FAX: 608-267-3695
dhfs.wisconsin.gov

To: Wisconsin Medical Use Licensees

From: Paul Schmidt, Chief
Radiation Protection Section

Date: July 21, 2009

Subject: Exemption from DHS 157 Requirements on Procurement and Transfer of Technetium-99m, and Calibration of Instrumentation Using Technetium-99m

The Department of Health Services is issuing the enclosed exemption from certain provisions in Ch. DHS 157, Wisconsin Administrative Code to all medical use licensees during times of molybdenum-99 shortages in the United States. This exemption is consistent with one recently issued by the Nuclear Regulatory Commission for NRC medical use licensees. The intent of the exemption is to assure that the available technetium-99m is used for patient administrations.

The supply chain for fission-produced medical isotopes is fragile and may shrink dramatically at any time when the aging international reactors that currently produce these isotopes are shut down for safety or routine maintenance. Therefore, this exemption may be needed intermittently until the supply of molybdenum-99 permanently stabilizes. The exemption should be kept with the license and discussed with the licensee's radiation safety officer and authorized users. The exemption can only provide relief from the Chapter DHS 157 rule; it does not provide relief from specific license conditions.

Contact Leola Dekock at 608 at 266-7384 or Leola.Dekock@wisconsin.gov or Cheryl Rogers at (608) 266-8135 or Cheryl.Rogers@wisconsin.gov if you believe that there are license conditions that also affect the availability of technetium-99m for patient treatments or if there are any questions about the exemption.

EXEMPTION FROM DHS 157 REQUIREMENTS ON PROCUREMENT AND TRANSFER OF TECHNETIUM-99m, AND CALIBRATION OF INSTRUMENTATION USING TECHNETIUM-99m

I. INTRODUCTION

All State of Wisconsin Medical Use Licensees are authorized for the medical use of radioactive material.

II. DISCUSSION

On May 14, 2009, the Chalk River National Research Universal reactor in Canada experienced an unexpected shutdown that has resulted in an extended shutdown for safety repairs. The Chalk River reactor produces approximately 50 percent of the United States supply of molybdenum-99 used to produce molybdenum-99/technetium-99m generators. This resulted in a United States and worldwide shortage of molybdenum-99 for generator production and technetium-99m for medical uses. The High Flux Reactor in Petten, Netherlands, also produces a substantial amount of molybdenum-99 used to produce generators in the United States and the world. The reactor in Petten is currently operating on a temporary operating permit and expected to be shutdown in early 2010 for a number of months for repairs. This will also cause molybdenum-99 and technetium-99m shortages in the United States and the world. The supply chain for fission-produced isotopes is fragile and may shrink dramatically at any time when these two, or the other three aging international reactors currently producing these isotopes, are shut down for safety or routine maintenance.

The Department is issuing exemptions from certain of its requirements in DHS 157.13(4)(i), DHS 157.62(1)(b), DHS 157.63(1)(a), DHS 157.63(2)(a), governing the sourcing and transfer of technetium-99m, and calibration of devices using technetium-99m. Each of these exemptions and the safety bases for exempting the licensee from these requirements is discussed below.

DHS 157.13(4)(i)

DHS 157.13(4)(i) specifies the requirements for manufacturing, preparation, or transfer for commercial distribution of radioactive drugs containing radioactive material for medical use under Chapter DHS 157, Subchapter VI. Licenses issued pursuant to this regulation are for commercial distribution of radioactive drugs to medical use licensees. Exempting the medical use licensee from the requirements in DHS 157.13(4)(i) permits the medical use licensee to transfer surplus molybdenum-99/technetium-99m generators or technetium-99m, or technetium-99m radioactive drugs, to other medical use licensees for administration to patients without requiring the licensee to meet the requirements for a commercial distributor of radioactive drugs. During times of technetium-99m shortages, this exemption will facilitate the transfer of surplus from a licensee that does not need it to one with patients that need technetium-99m procedures. The material has to be prepared and transported in accordance with the radioactive materials transportation requirements using adequate shielding, appropriate containers, and the proper radioactive shipping labels. Further, the activities and short half lives of the molybdenum-99 and

technetium-99m make it highly unlikely that granting this exemption will endanger life or property or common defense and security. The exemption is in the public interest because it makes needed radioactive material available for necessary patient treatment.

DHS 157.62(1)(b)

DHS 157.62(1)(b) requires licensees to calibrate instrumentation required in paragraph (a) of DHS 157.62(1)(a) in accordance with manufacturer's instructions. Manufacturer's instructions specify that instruments used to measure patient dosages are checked for linearity at the maximum activities measured. The maximum activity may be for multidose vials, generator elutions, or high activity dosages of technetium-99m or other radionuclides, such as iodine-131. The calibration tests are most frequently performed with technetium-99m because it is normally easy to obtain from suppliers and has a short half-life. Under the exemption, the licensee will not be required to perform the calibration test at the maximum activity or at the time interval specified in the manufacturer's instructions if the licensee would use technetium-99m that is needed to administer to a patient to perform the calibration test. The exemption will only be in effect when the licensee is receiving reduced quantities of technetium-99m as a result of production shortages of molybdenum-99 affecting its generator or technetium-99m supplier, as documented in writing by the supplier. The licensee must perform the test when adequate supplies become available, and must document the results of the test in accordance with DHS 157.71(6). During shortage periods, it is expected that the licensee will perform the test with lower activities if the test can be performed using material that is either not needed for patient administration or at the completion of the test can still be used for patient administration. In this case, the licensee will have confidence that over those ranges the instrument is still operational and calibrated. In times of extreme shortage, the licensee may have to postpone performing the test altogether. Most instruments used to measure patient dosages today are stable if not moved and provided with reasonable climate controls. Not granting the exemption will make fewer dosages available to patients and result in licensees not being able to use these instruments even though they are calibrated at the levels of routine technetium-99m dosages. Once adequate supplies become available and the licensee performs the tests in accordance with the manufacturer's instructions, the instruments that pass the calibration test at that time can be assumed to have been calibrated while the exemption was in effect. The world supply of molybdenum-99 is very fragile because it depends on aging reactors that may be shut down for safety or maintenance at any time. Therefore, because of the uncertainty of continued availability, the test must be performed as soon as adequate supplies are available, as indicated in the provisions of the exemption. The test must not be postponed to the next specified time interval, to avoid conflict with a subsequent shortage. For higher dosages requiring written directives the licensee will have to depend upon the activity provided with the radioactive drug to assure patient safety associated with the administration. The exemption will not endanger life or property or common defense and security because it does not relieve the licensee from the Department's requirements for worker dose or public dose, handling or securing the radioactive materials, or handling or securing radioactive waste associated with performing the test. All of those protections remain in place. Also, both molybdenum-99 and technetium-99m have short half-lives and the proposed exemption does not affect how the licensee handles these radionuclides. The exemption is in the public interest because it provides for performing calibration test at levels of activity being used, makes needed technetium-99m available to

patients, and assures that when the supplies of technetium-99m become available, the calibration is performed in accordance with manufacturer's instructions.

DHS 157.63(1)(a) and DHS 157.63(2)(a)

DHS 157.63(1)(a) and DHS 157.63(2)(a) require medical use licensees to obtain unsealed radioactive material prepared for medical use for uptake, dilution, excretion, imaging or localization studies from a manufacturer or preparer licensed under DHS 157.13(4)(i), NRC or equivalent Agreement State requirements. The exemption would permit the licensee to obtain the technetium-99m (or a technetium-99m radioactive drug) from another medical use licensee to administer to patients. This permits medical use licensees with patients that need technetium-99m procedures that cannot get technetium-99m from their normal supplier because of the shortage to obtain the needed technetium-99m from a local medical use licensee that has a surplus. This exemption will only be in effect when the licensee is unable to obtain technetium-99m (or a technetium-99m radioactive drug) from its normal supplier as a result of production shortages of molybdenum-99 affecting its generator or technetium-99m supplier, as documented in writing by the supplier. This exemption will give some relief on a case-by-case basis to a medical use licensee if its supplier is severely affected by the shortage but the other medical use licensee supplier is not. The activities and short half-lives of the molybdenum-99 and technetium-99m make it highly unlikely that granting this exemption will endanger life or property or common defense and security. The exemption is in the public interest because it makes needed radioactive material available for necessary patient treatment.

DHS 157.04(1) authorizes the Department to issue exemptions from the requirements of Chapter DHS 157. For the reasons set forth above, the Department concludes that exemptions from the Department's requirements in DHS 157.13(4)(i), DHS 157.62(1)(b), DHS 157.63(1)(a), DHS 157.63(2)(a), as set forth below, are authorized by law and will not endanger public health and safety, property or the common defense and security, and are in the public interest.

III. EXEMPTION

1. Notwithstanding the requirements in DHS 157.62(1)(b) to calibrate the instrumentation required in paragraph (a) of this section in accordance with manufacturer's instructions, the licensee is not required to perform the calibration test at the maximum activity or at the time interval specified in the manufacturer's instructions if: (i) the licensee would use technetium-99m that is needed to administer to a patient to perform the test; (ii) the licensee certifies in writing that the quantities of technetium-99m that it is receiving from its supplier is less than what the licensee has ordered or procured and is not sufficient to perform the test in accordance with the manufacturer's instructions; and (iii) the licensee's supplier provides written documentation that the supplier is providing reduced quantities of technetium-99m to the licensee as a result of production shortages of molybdenum-99 affecting its generator or technetium-99m. **[NOTE: IF THERE IS A CALIBRATION LICENSE CONDITION, THE LICENSEE NEEDS TO TAKE AN ACTION TO AMEND THE CONDITION TO ALLOW THE CHANGE IN CALIBRATION; THE EXEMPTION BY ITSELF WILL NOT ALLOW THE LICENSEE TO ACCOMPLISH THESE ACTIONS]** The licensee must perform the calibration test as soon as adequate supplies become available, and document results of the test in

accordance with DHS 157.62(1)(b). If adequate supplies become available, the licensee cannot defer performing the tests until the next time interval. The licensee shall maintain records of its certification and the underlying documentation supporting the licensee's certification, and the supplier's written documentation for 3 years.

2. Notwithstanding the requirements in DHS 157.63(1)(a) and DHS 157.63(2)(a) to obtain unsealed radioactive material prepared for medical use for uptake, dilution, excretion, imaging or localization studies from a manufacturer or preparer licensed under DHS 157.13(4)(i), NRC or equivalent Agreement State requirements, the licensee may obtain technetium-99m, or dosages of technetium-99m radioactive drugs, from another Wisconsin medical use licensee to administer to patients when the licensee is unable to obtain technetium-99m (or unit dosage of a technetium-99m radioactive drug) from its normal supplier as a result of production shortages of molybdenum-99 affecting its generator or technetium-99m supplier, as documented in writing by the supplier. The licensee shall certify in writing that it is receiving reduced qualities of technetium-99m from its supplier and did not have enough to provide the administration(s). The licensee shall maintain a record of the transfer, its certification and the underlying documentation supporting the licensee's certification, and the supplier's certification for 3 years.
3. Notwithstanding the requirements in DHS 157.13(4)(i), the licensee may transfer surplus technetium-99m, or dosages of technetium-99m radioactive drugs, to other medical use licensees licensed by the Department, for administration to patients, but only after the licensee obtains from the receiving medical use licensee a written certification that it is unable to obtain a generator, or technetium-99m or unit dosages of a technetium-99m radioactive drug from its normal supplier as a result of production shortages of molybdenum-99 affecting its generator or technetium-99m supplier. The licensee shall maintain a record of the transfer and the receiving licensee's certification for 3 years.
4. Nothing in this exemption relieves the licensee from complying with the requirements in DHS 157.59(2).
5. This exemption is effective upon issuance and during periods of United States shortages of molybdenum-99 and technetium-99m as documented in writing by the suppliers of molybdenum-99/technetium-99m generators and technetium-99m radioactive drugs.
6. This exemption should be kept with the license and discussed with the licensee's Radiation Safety Officer and Authorized Users.

Paul Schmidt, Chief
Radiation Protection Section